Last reviewed · How we verify

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias — Portfolio Competitive Intelligence Brief

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Bio-Path Holdings, Inc. · 1 shared drug class
  4. Otsuka Australia Pharmaceutical Pty Ltd · 1 shared drug class
  5. Race Oncology Ltd · 1 shared drug class
  6. Shirley Ryan AbilityLab · 1 shared drug class
  7. Taiho Oncology, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias:

Cite this brief

Drug Landscape (2026). Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grupo-cooperativo-de-estudio-y-tratamiento-de-las-leucemias-agudas-y-mielodispla. Accessed 2026-05-18.

Related